| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.87 [0.66, 1.14] | | < 1 | | 0% | 1 study (1/-) | 84.1 % | NA | not evaluable | | crucial | - |
| MFS | 0.64 [0.47, 0.87] | | < 1 | | 48% | 2 studies (2/-) | 99.8 % | low | not evaluable | high | important | - |
| RFS (extension) | 0.63 [0.50, 0.80] | | < 1 | | 69% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | important | - |
| RFS/DFS | 0.59 [0.50, 0.70] | | < 1 | | 0% | 4 studies (4/-) | 100.0 % | low | not evaluable | high | important | - |
| DMFS | 0.60 [0.49, 0.73] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.93 [0.31, 2.76] | | < 1 | | 78% | 2 studies (2/-) | 55.4 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 0.75 [0.11, 5.30] | | < 1 | | 99% | 2 studies (2/-) | 61.3 % | low | not evaluable | high | non important | - |
| AE leading to death (grade 5) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.74 [0.07, 44.47] | | < 1 | | 97% | 3 studies (3/-) | 37.0 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 1.73 [0.05, 61.70] | | < 1 | | 97% | 3 studies (3/-) | 38.4 % | low | not evaluable | high | non important | - |
| SAE (any grade) | 2.18 [0.76, 6.21] | | < 1 | | 71% | 2 studies (2/-) | 7.3 % | low | not evaluable | high | non important | - |
| SAE (grade 3-4) | 3.06 [1.65, 5.67] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| STRAE (any grade) | 5.79 [2.74, 12.21] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| STRAE (grade 3-4) | 5.30 [2.27, 12.38] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| TRAE (any grade) | 1.61 [0.44, 5.95] | | < 1 | | 94% | 4 studies (4/-) | 23.7 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 2.42 [0.28, 21.04] | | < 1 | | 98% | 4 studies (4/-) | 21.4 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 0.76 [0.13, 4.44] | | < 1 | | 0% | 4 studies (4/-) | 62.1 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 2.01 [0.06, 73.17] | | < 1 | | 98% | 3 studies (3/-) | 35.4 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.93 [0.04, 97.28] | | < 1 | | 97% | 3 studies (3/-) | 37.4 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.74 [0.09, 6.38] | | < 1 | | 0% | 3 studies (3/-) | 60.7 % | low | not evaluable | high | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 1.45 [0.11, 19.13] | | < 1 | | 0% | 2 studies (2/-) | 39.0 % | low | not evaluable | high | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 0.81 [0.22, 2.99] | | < 1 | | 0% | 4 studies (4/-) | 62.6 % | low | not evaluable | high | non important | - |
| Alopecia TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Anaemia TRAE (grade 3-4) | 1.45 [0.11, 19.13] | | < 1 | | 0% | 2 studies (2/-) | 39.0 % | low | not evaluable | high | non important | - |
| Arthralgia TRAE (grade 3-4) | 1.16 [0.27, 4.96] | | < 1 | | 3% | 4 studies (4/-) | 42.1 % | low | not evaluable | high | non important | - |
| Asthenia TRAE (grade 3-4) | 0.25 [0.03, 2.24] | | < 1 | | 0% | 1 study (1/-) | 89.1 % | NA | not evaluable | | non important | - |
| Blood and lymphatic system disorders TRAE (grade 3-4) | 3.02 [0.28, 33.13] | | < 1 | | 0% | 2 studies (2/-) | 18.5 % | low | not evaluable | high | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.91 [0.02, 46.72] | | < 1 | | 0% | 1 study (1/-) | 51.8 % | NA | not evaluable | | non important | - |
| Chills TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Colitis TRAE (grade 3-4) | 6.10 [1.28, 29.09] | | < 1 | | 0% | 3 studies (3/-) | 1.2 % | low | not evaluable | high | non important | - |
| Cough TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Diabetes TRAE (grade 3-4) | 2.37 [0.46, 12.12] | | < 1 | | 0% | 4 studies (4/-) | 15.0 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.57 [0.13, 2.58] | | < 1 | | 64% | 4 studies (4/-) | 76.7 % | low | not evaluable | high | non important | - |
| Dizziness TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Dyspepsia TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Dyspnoea TRAE (grade 3-4) | 1.28 [0.15, 11.07] | | < 1 | | 0% | 3 studies (3/-) | 41.0 % | low | not evaluable | high | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 6.23 [1.33, 29.21] | | < 1 | | 0% | 3 studies (3/-) | 1.0 % | low | not evaluable | high | non important | - |
| Eye disorders TRAE (grade 3-4) | 1.45 [0.11, 19.13] | | < 1 | | 0% | 2 studies (2/-) | 39.0 % | low | not evaluable | high | non important | - |
| Fatigue TRAE (grade 3-4) | 0.60 [0.14, 2.55] | | < 1 | | 0% | 3 studies (3/-) | 75.7 % | low | not evaluable | high | non important | - |
| Gastritis TRAE (grade 3-4) | 2.32 [0.20, 26.84] | | < 1 | | 0% | 2 studies (2/-) | 25.1 % | low | not evaluable | high | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 1.57 [0.10, 24.07] | | < 1 | | 91% | 4 studies (4/-) | 37.4 % | low | not evaluable | high | non important | - |
| General disorders and administration site conditions TRAE (grade 3-4) | 2.32 [0.20, 26.84] | | < 1 | | 0% | 2 studies (2/-) | 25.1 % | low | not evaluable | high | non important | - |
| Headache TRAE (grade 3-4) | 0.28 [0.05, 1.51] | | < 1 | | 0% | 3 studies (3/-) | 92.9 % | low | not evaluable | high | non important | - |
| Hepatitis TRAE (grade 3-4) | 4.29 [1.30, 14.20] | | < 1 | | 0% | 3 studies (3/-) | 0.9 % | low | not evaluable | high | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 1.42 [0.07, 29.90] | | < 1 | | 91% | 3 studies (3/-) | 41.2 % | low | not evaluable | high | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 2.01 [0.07, 59.97] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Hypertension TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.93 [0.39, 9.56] | | < 1 | | 0% | 4 studies (4/-) | 21.1 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.70 [0.13, 3.88] | | < 1 | | 39% | 4 studies (4/-) | 65.9 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.71 [0.14, 3.70] | | < 1 | | 0% | 4 studies (4/-) | 65.7 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 1.04 [0.07, 14.37] | | < 1 | | 84% | 3 studies (3/-) | 48.9 % | low | not evaluable | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.55 [0.11, 22.65] | | < 1 | | 89% | 3 studies (3/-) | 37.6 % | low | not evaluable | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 1.80 [0.56, 5.76] | | < 1 | | 16% | 2 studies (2/-) | 16.2 % | low | not evaluable | high | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 0.37 [0.04, 3.82] | | < 1 | | 31% | 3 studies (3/-) | 79.6 % | low | not evaluable | high | non important | - |
| Metabolism and nutrition disorders TRAE (grade 3-4) | 1.29 [0.15, 11.24] | | < 1 | | 0% | 2 studies (2/-) | 40.9 % | low | not evaluable | high | non important | - |
| Musculoskeletal and connective tissue disorders TRAE (grade 3-4) | 0.96 [0.03, 31.61] | | < 1 | | 63% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Myalgia TRAE (grade 3-4) | 0.96 [0.09, 10.77] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | low | not evaluable | high | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.97 [0.07, 58.99] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 0.97 [0.10, 9.40] | | < 1 | | 0% | 3 studies (3/-) | 51.0 % | low | not evaluable | high | non important | - |
| Nausea TRAE (grade 3-4) | 1.21 [0.18, 8.02] | | < 1 | | 0% | 4 studies (4/-) | 42.0 % | low | not evaluable | high | non important | - |
| Nephritis TRAE (grade 3-4) | 3.96 [0.18, 87.96] | | < 1 | | 0% | 1 study (1/-) | 19.5 % | NA | not evaluable | | non important | - |
| Nervous system disorders TRAE (grade 3-4) | 1.07 [0.16, 7.27] | | < 1 | | 0% | 2 studies (2/-) | 47.3 % | low | not evaluable | high | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Pancreatitis TRAE (grade 3-4) | 0.97 [0.14, 6.96] | | < 1 | | 0% | 3 studies (3/-) | 51.0 % | low | not evaluable | high | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 1.45 [0.11, 19.13] | | < 1 | | 0% | 2 studies (2/-) | 39.0 % | low | not evaluable | high | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.61 [0.35, 19.72] | | < 1 | | 0% | 3 studies (3/-) | 17.8 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 0.41 [0.07, 2.45] | | < 1 | | 0% | 4 studies (4/-) | 83.5 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.99 [0.14, 6.74] | | < 1 | | 0% | 3 studies (3/-) | 50.5 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 0.41 [0.15, 1.09] | | < 1 | | 0% | 2 studies (2/-) | 96.3 % | low | not evaluable | high | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 1.00 [0.02, 50.62] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 0.98 [0.15, 6.59] | | < 1 | | 22% | 4 studies (4/-) | 50.8 % | low | not evaluable | high | non important | - |
| Sarcoidosis TRAE (grade 3-4) | 0.97 [0.10, 9.40] | | < 1 | | 0% | 3 studies (3/-) | 51.0 % | low | not evaluable | high | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 5.95 [0.30, 119.02] | | < 1 | | 0% | 1 study (1/-) | 12.5 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 0.85 [0.14, 5.17] | | < 1 | | 59% | 4 studies (4/-) | 57.0 % | low | not evaluable | high | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 1.45 [0.11, 19.13] | | < 1 | | 0% | 2 studies (2/-) | 39.0 % | low | not evaluable | high | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.97 [0.10, 9.40] | | < 1 | | 0% | 3 studies (3/-) | 51.0 % | low | not evaluable | high | non important | - |
| Uveitis TRAE (grade 3-4) | 0.97 [0.10, 9.40] | | < 1 | | 0% | 3 studies (3/-) | 51.0 % | low | not evaluable | high | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.97 [0.10, 9.40] | | < 1 | | 0% | 3 studies (3/-) | 51.0 % | low | not evaluable | high | non important | - |
| Vomiting TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
